Data protection Impressum

Life sciences

The University Hospitals of Geneva (HUG) have introduced Switzerland’s first AI-driven medical chatbot, “confIAnce”, providing reliable, verified general medical information. This innovation represents a major step in integrating artificial intelligence into Swiss healthcare.

HUG pioneers AI-powered healthcare with Switzerland’s first medical chatbot

10 February 2025

Biotech company CELLnTEC is playing a key role in the NEOLIVER project, a European-Swiss initiative developing the world’s first autologous bioprinted liver for clinical use. The project, co-funded by the EU and the Swiss government, aims to address the global organ donor shortage through innovative bioprinting technologies.

Bern-based CELLnTEC joins NEOLIVER project to develop bioprinted liver constructs

10 February 2025

The Swiss Institute of Bioinformatics has inaugurated the Centre for Pathogen Bioinformatics in Bern, a state-of-the-art facility dedicated to strengthening genomic surveillance of infectious diseases.

The Centre for Pathogen Bioinformatics was inaugurated in Bern

4 February 2025

The Lausanne University Hospital (CHUV) has secured market authorization from Swissmedic to produce a fecal microbiota transplant (FMT) medication, making it the first accredited center in Switzerland to manufacture this treatment under strict pharmaceutical standards. This breakthrough provides an effective solution for patients suffering from recurrent Clostridioides difficile infections, a debilitating condition characterized by repeated digestive blowouts and severe discomfort.

CHUV becomes first Swiss hospital to produce gut-balancing medication

29 January 2025

The Human Lean Diagnostics (HLD) innovation cluster in Neuchâtel is preparing to welcome its first tenants in June 2025. Developed in collaboration with Microcity, the cluster is dedicated to accelerating medical diagnostics innovation by providing state-of-the-art infrastructure, fostering collaboration between industry and academia, and strengthening Switzerland’s position in health technology.

Neuchâtel’s Human Lean Diagnostics cluster is set to welcome its first tenants

29 January 2025

TheraMe!, a Lausanne-based medtech, is transforming cancer treatment by partnering with CSEM to develop an automated, microfluidic-based instrument. This breakthrough technology enables personalized drug screening on live tumor samples, providing cancer patients with tailored therapy recommendations before treatment begins.

CSEM and TheraMe! transform cancer therapy with personalized drug screening technology

28 January 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

EBAMed has secured an additional EUR 1.6 million in Series A funding, bringing the total raised to EUR 16 million. This new investment, contributed by CDP Venture Capital and the European Union, supports the development of EBAMed’s groundbreaking CardioKit system for non-invasive treatment of heart arrhythmias using Proton Therapy.

Geneva medtech EBAMed completes financing round with EUR 16 million

27 January 2025

Geneva-based BrainScape Medical, a newly incorporated company specializing in neuromonitoring and neurostimulation technologies, has announced several milestones, including new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.

BrainScape Medical makes strides in long-term brain monitoring

21 January 2025

Start-up Aspivix has raised EUR 1.95 million through a crowdfunding campaign to advance the commercialization of its innovative gynecological device, Carevix™. The campaign, hosted on the Capital Cell platform, aims to reach a target of EUR 2.15 million by 15 March 2025.

Medtech Aspivix secures EUR 1.95 million in crowdfunding

20 January 2025

1 2 3 4 5 6 7 8 9 … 43